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Abstract
Background: Interventions to promote prevention and earlier diagnosis of severe symptomatic hyperlactataemia 
(SHL) were implemented in the Western Cape provincial antiretroviral programme (South Africa) from 2004. 
Interventions included clinician education, point-of-care lactate meters, switch from stavudine to zidovudine in high 
risk patients and stavudine dose reduction. This study assessed trends in referral rate, severity at presentation and case 
fatality rate for severe SHL.
Methods: Retrospective study of severe SHL cases diagnosed at a referral facility from 1 January 2003 to 31 December 
2008. Severe SHL was defined as patients with compatible symptoms and serum lactate ≥ 5 mmol/l attributable to 
antiretroviral therapy (ART). Cumulative ART exposure at referring ART clinics was used to calculate referral rates.
Results: There were 254 severe SHL cases. The referral rate (per thousand patient years [py] ART exposure) peaked in 
2005 (20.4/1000py), but fell to 1.3/1000py by 2008 (incidence rate ratio [IRR] = 0.07, 95%CI 0.04-0.11). In 2003, 66.7% of 
cases presented with a standard bicarbonate (SHCO3) level <15 mmol/l, but this fell to 12.5% by 2008 (p for trend < 
0.001). Case fatality rate fell from a peak of 33.3% in 2004 to 0% in 2008 (p for trend = 0.002).
Conclusions: These trends suggest the interventions were associated with reduced referral, less severe metabolic 
acidosis at presentation and improved survival.
Background
Recent studies from large antiretroviral therapy (ART)
cohorts in resource-limited countries have reported
symptomatic hyperlactataemia (SHL) and lactic acidosis
(LA) as frequent complications of ART [1-7]. The inci-
dence of SHL/LA in sub-Saharan Africa has been
reported to be between 10 - 21 per thousand patient years
(py) on ART [1-3], [6] with mortality between 16 and 57%
[1-6]. An important reason is that sta vudine (the drug
most frequently implicated as the cause of SHL and LA
via mitochondrial toxicity) is used in standardized first
line ART regimens in many resource limited settings due
to its relative affordability.
Based on preliminary data regarding the high incidence
and risk factors for SHL/LA in sub-Saharan Africa, sev-
eral interventions were implemented in the Western
Cape provincial ART programme in South Africa from
2004. The aim was to prevent SHL/LA and facilitate ear-
lier diagnosis thereby improving prognosis. These inter-
ventions were: 1) clinician education and clinical
guideline development on risk factors, prevention, clini-
cal presentation, diagnosis and management (imple-
mented from 2004) [8]; 2) distribution of point-of-care
lactate meters to ART clinics from 2005 with full cover-
age by the end of 2006; 3) a clinical guideline advising that
z i d o v u d i n e  r a t h e r  t h a n  s t a v u d i n e  b e  u s e d  i n  f i r s t  l i n e
ART in women with a body mass index >28 (January
2006); and 4) reduction of the stavudine dose from 40 mg
twice daily to 30 mg twice daily for those > 60 kg (Febru-
ary 2007). The preventative switch to zidovudine was
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based on evidence that overweight women were at higher
risk for SHL/LA [1-3], [5,9,10]. The stavudine dose
reduction was based on a systematic review that showed
a reduction in side effects but equivalent virological out-
comes with the lower dose [11]. The point-of-care lactate
meters used in primary care clinics were Roche Accu-
trend® meters that were provided by the Western Cape
provincial government and have been validated for the
d i a gn os i s  o f  NR T I - r e la t ed  S H L / LA  i n  r e so u r c e  l i m i t ed
settings[12].
We aimed to assess the impact of these preventive
interventions in terms of trends in referral rate for severe
SHL to our facility and, among those diagnosed with
severe SHL, trends in severity of metabolic acidosis a t
presentation and case fatality rate.
In the Western Cape Province, ART provision in the
public sector began at four pilot clinics in 2001-2 [13-15]
and was followed by the wider government scale-up of
ART in April 2004. Three of the four pilot clinics started
with zidovudine-based ART, but by September 2003 all
public sector clinics were providing a standardized first
line of stavudine, lamivudine and either efavirenz or nevi-
rapine [16]. Zidovudine was used instead of stavudine in
pregnant women. GF Jooste Hospital, where the study
was undertaken, is a referral hospital for all primary care
ART clinics in surrounding communities. Only patients >
12 years old are seen at the hospital. There were 3 large
public sector ART clinics referring to GF Jooste Hospital
at the start of the study period, but this increased to 11
clinics by the end of the study period. All patients with
significant ART related complications, including all with
suspected SHL/LA, were referred to GF Jooste Hospital.
Provincial guidelines stated all patients with clinically
suspected SHL or LA and all patients with lactate > 4
mmol/l measured on point-of-care lactate meter in pri-
mary care should be referred to the appropriate second-
ary level hospital for assessment and laboratory lactate
measurement. These guidelines were the same for all pri-
mary care ART clinics in the referral area.
A previous study from our hospital describing the clini-
cal features of severe SHL was conducted between
August 2003 and November 2005. It included 75 cases, all
of whom are also included in this paper . In the earlier
study, 95% of patients were female, the median age was 33
years (range 21 - 57), and median duration of ART at pre-
sentation was 10 months (interquartile range [IQR] 8 -
12). All patients were on a stavudine containing regimen
or had recently switched from stavudine to zidovudine (8
patients had switched to zidovudine within the preceding
3 weeks). 71% of the patients were found to have meta-
bolic acidosis (standard bicarbonate [SHCO3] < 20
mmol/l) [2].
Methods
A retrospective observational study from 1 January 2003
to 31 December 2008 was conducted. Laboratory and
patient records were reviewed and all cases with severe
SHL, defined by compatible symptoms and a serum lac-
tate of ≥5 mmol/l were included, provided the hyperlacta-
taemia was attributable to ART. Patients were excluded if
they had another acute illness that was more likely the
cause of hyperlactataemia. Reasons for exclusion were
severe dehydration, hepatic failure, sepsis and severe
anaemia. However, if the lactate remained elevated after
treatment of the acute condition, suggesting underlying
NRTI-related mitochondrial toxicity, the patient was
included. The study period was divided into 6 calendar
years. The referral rate for severe SHL was calculated
using two methods. For the first calculation, the denomi-
nator used was the cumulative ART exposure among
adult patients at the referring ART clinics over that
period, based on monthly reports of total patients in care
in each referring clinic at the end of each month [15]. For
the second calculation, the denominator used was the
cumulative adult ART exposure of patients on ART for
between 6-18 months duration. We performed the sec-
ond calculation to correct for potential biasing effect of
more patients in the denominator being beyond the "win-
dow of risk" for severe SHL in later calendar years. This
"window of risk" has been reported to be between 6 and
18 months on ART from several studies conducted in
resource limited settings where stavudine was used in
first line ART. Most patients in these studies were on sta-
vudine when they developed SHL or LA [1-7].
Venous blood samples for lactate were taken without a
tourniquet, into a fluoride oxalate containing tube, and
rapidly transported to the laboratory for processing. Lac-
tate was measured on a Beckman-Coulter Synchron CX®
system. Blood gas for pH and SHCO3  were done on
venous or arterial blood samples. Our laboratory uses a
reference range of 0.6-2.45 mmol/l to define normal
s e r u m  l a c t a t e .  A  v a l u e  o f  5  m m o l / l  w a s  t h u s  u s e d  t o
define severe SHL because this is twice the upper limit of
normal. SHCO3 level < 15 mmol/l at presentation was
used as an indicator of more severe metabolic acidosis. A
previous study done at our hospital showed that SHCO3
level <15 mmol/l was associated with acute mortality
(odds ratio = 22.5, 95% confidence interval [95% CI] 2.8-
1,045.7) [2]. Univariate Poisson regression analysis was
used to calculate incidence rate ratios (IRRs) for referral
rates. The non-parametric test for trend across ordered
groups was used to assess trends in median SHCO3 level
at presentation. The chi-squared test for trend was used
to assess trends with respect to proportions. Permission
for the study was obtained from the University of CapeSchutz et al. AIDS Research and Therapy 2010, 7:13
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Town Research Ethics Committee (REC REF: 312/2005
and 431/2009).
Results
Two hundred and fifty nine (259) cases of severe SHL
presented during the study period. Folders were missing
for 5, thus 254 cases were included in the analysis. Sev-
enty five of these cases have been included in previous
reports [2,10]. Two hundred and twenty three (87.8%)
were female with a median age of 35 (IQR 29 - 41.5). The
31 male patients had a median age of 42 (IQR 36.5 - 46).
The first case presented in August 2003. During the study
period the number of adult patients on ART in our refer-
ral area increased from 268 in January 2003 to 13 985 in
December 2008.
Trends in referral rate are shown in Figure 1 and Table
1. The referral rate peaked in 2005, but fell significantly
by 2007 and 2008. Using cumulative adult ART exposure
in the referral area as the denominator and 2005 as the
reference, the IRR was 0.3 (95% CI = 0.21-0.43) for 2007
and 0.07 (95% CI = 0.04-0.11) for 2008. There was a simi-
lar decrease in referral rates from 2005 to 2007 and 2008
using adult ART exposure of 6-18 months duration as the
denominator. Trends in SHCO3 level at presentation and
case fatality rate are shown in Table 2. The median
SCHO3 at presentation increased over the study period (p
for trend < 0.001) resulting in a decrease in the propor-
tion of cases with SCHO3 level < 15 mmol/l at presenta-
tion (p for trend < 0.001). The case fatality rate dropped
substantially from 2004 to 2008 (p for trend = 0.002).
Discussion
Despite a growing number of patients on ART at the pri-
mary care clinics in the referral area of our hospital, the
referral rate, severity of metabolic acidosis at presenta-
tion and case fatality rate for severe SHL fell during the
study period. It is likely that the preventative switch to
zidovudine in overweight women and lowering the stavu-
dine dose led to reduced incidence which resulted in a
reduced referral rate. Heightened clinician vigilance and
the availability of a point-of-care test in primary care clin-
ics likely led to earlier detection of SHL and more proac-
tive substitutions in the primary care setting.
The proportion of females starting ART in our referral
area has not changed substantially since 2003. In 2003,
females accounted for 68.9% of adults starting ART in our
referral area, and in 2008, 66.1% of adults starting ART
were female. Female gender is a risk factor for severe SHL
Figure 1 Referral rates for severe symptomatic hyperlactataemia. The referral rates from 2003 to 2008 are shown with 95% confidence intervals. 
The empty circles demonstrate referral rates using cumulative antiretroviral therapy (ART) exposure of all adult patients at referral clinics as the de-
nominator. The solid squares demonstrate referral rates using cumulative adult ART exposure of between 6 and 18 months duration as the denomi-
nator. SHL = symptomatic hyperlactataemia; py = patient years, ART = antiretroviral therapySchutz et al. AIDS Research and Therapy 2010, 7:13
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Table 1: Case load and referral rates for severe symptomatic hyperlactataemia cases (2003-2008)
Time Period Number of 
severe SHL cases
Cumulative 
adult 
ART exposure 
(years)
Referral rate: 
cases/1000 
py ART 
exposure (95% CI)
IRR(95% CI) Cumulative ART 
exposure 
6-18 months (years)
Referral rate: 
cases/1000 py 6-18 
months on 
ART (95% CI)
IRR(95%CI)
2003 4 436 9.2
(3.4-24.4)
0.45
(0.16-1.24)
219 18.3
(6.9-48.7)
0.46
(0.17-1.26)
2004 15 1361 11.0
(6.6-18.3)
0.54
(0.31-0.95)
547 27.4
(16.5-45.5)
0.69
(0.39-1.21)
2005 67 3292 20.4
(16.0-25.9)
1.0 (ref) 1689 39.7
(31.2-50.4)
1.0 (ref)
2006 99 6069 16.3
(13.4-19.9)
0.8
(0.59-1.09)
3284 30.1
(24.8-36.7)
0.76
(0.56-1.04)
2007 53 8771 6.0
(4.6-7.9)
0.3
(0.21-0.43)
4442 11.9
(9.1-15.6)
0.30
(0.21-0.43)
2008 16 12014 1.3
(0.8-2.2)
0.07
(0.04-0.11)
4488 3.6
(2.2-5.8)
0.09
(0.05-0.16)
Entire
Period
254 31943 8.0
(7.0-9.0)
- 14669 17.3 (15.3-19.6) -
1 Incidence rate ratio was calculated using 2005 as reference period.
SHL = Symptomatic Hyperlactataemia, ART = Antiretroviral therapy, py = patient years, CI = Confidence interval, IRR = Incidence rate ratio.
Table 2: Standard bicarbonate levels and case fatality rates for severe symptomatic hyperlactataemia cases (2003-2008)
Time Period Number of 
severe SHL cases
Number who 
had SHCO3 
performed (%)
Median 
SHCO3 (IQR)1
Number with SHCO3 
level <15 mmol/l (%)2
Number of deaths
 (case fatality rate as%)3
2003 4 3 (75) 14.2 (5.1-19.8) 2 (66.7) 0 (0)
2004 15 14 (93.3) 15.5 (4.9-18) 7 (50) 5 (33.3)
2005 67 55 (82.1) 17.6 (13.5-20) 19 (34.5) 7 (10.4)
2006 99 89 (89.9) 19.8 (17-21.3) 13 (14.6) 5 (5.1)
2007 53 49 (92.5) 20.1 (18-21.2) 6 (12.2) 3 (5.7)
2008 16 16 (100) 20 (17.3-21.4) 2 (12.5) 0 (0)
Entire
period
254 226 (89) 19.1 (15.8-20.9) 49 (21.7) 20 (7.9)
1 Median standard bicarbonate level: p for trend < 0.001 (for period 2003-2008).
2 Proportion with standard bicarbonate < 15 mmol/l: p for trend < 0.001 (for period 2003-2008). The proportion was calculated using the 
number who had standard bicarbonate performed during that year as denominator, see column 3.
3Case fatality rate: p for trend = 0.002 (for period 2004 - 2008; 2003 was excluded as case fatality rate peaked in 2004).
SHL = Symptomatic Hyperlactataemia, SHCO3 = Standard bicarbonate in mmol/l (normal range 21-26 mmol/l), IQR = interquartile range.Schutz et al. AIDS Research and Therapy 2010, 7:13
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[1-3], [5,6], [9,10]. It is unlikely that the reduction in
severe SHL referral rate that we observed was accounted
for by this relatively small reduction in the proportion of
females starting ART.
Inpatient management of severe SHL at our facility
(which includes intravenous fluids, intravenous bicarbon-
ate in those with severe metabolic acidosis, intravenous
thiamine/vitamin B complex and empiric broad-spec-
trum antibiotics [2]) did not change during the study
period. Specifically, there was also no change in the man-
agement of patients who were critically ill with lactic aci-
dosis who were admitted to the high care unit throughout
the study period for full supportive management which
included broad-spectrum intravenous antibiotics to treat
possible sepsis.
Thus the improved survival is likely attributable to ear-
lier diagnosis, as evidenced by less severe metabolic aci-
dosis at presentation in the later calendar years. In 2004
the mortality rate was 33.3%, which correlates with the
mortality rate reported from other resource-limited set-
tings [1-6]. The mortality rate decreased after 2004 and
remained low , with no deaths due to SHL recorded in
2008.
This was a retrospective folder review, which has
important limitations. We were dependant on clinical
notes from attending clinicians. We also assumed that cli-
nicians in primary care ART clinics detected and referred
cases consistently throughout the study period. Any
change in referral practice may have introduced selection
bias. However, our experience is that referral practices
have improved over time as the ART programme has
matured making this an unlikely cause of the reduced
referral rates we observed.
It is possible that patients with severe SHL could have
died before being referred or could have died acutely in
the casualty unit without collateral history and before lac-
ta t e  was m eas ur ed.  T h us  we  r epo rt ed t he  r ef e rr a l r a t e
rather than an incidence rate, but it is likely that the refer-
ral rate approximates the incidence rate as all cases of
suspected and confirmed severe SHL are referred from
primary care ART facilities to our hospital. The referral
rates during 2004 and 2005, prior to the impact of the
interventions, are comparable to incidence rates reported
from elsewhere in sub-Saharan Africa [1-3], [6]. We did
not capture detailed clinical data on the cases and are
unable to report on current ART regimen, duration of
ART or stavudine dose among the cases in this study.
Conclusions
These trends suggest the measures implemented resulted
in reduced incidence, earlier diagnosis and thus less
severe presentations and improved survival of patients
with severe SHL in our referral area. Furthermore it dem-
onstrates how through pharmacovigilance within large
public health programs, early warning signs can lead to
beneficial interventions that may mitigate ART adverse
events. Mitochondrial toxicity associated with stavudine,
however, still causes significant morbidity in the form of
neuropathy [17] and lipoatrophy in our setting and alter-
natives to stavudine are required.
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